Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults

References

• Kuijper EJ, Coignard B, Tüll P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2–18.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825–834.
   PubMed Web of Science ®Google Scholar
• Abou Chakra CN, Pepin J, Sirard S, et al. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One. 2014;9:e98400.
   PubMed Web of Science ®Google Scholar
• Kim HH, Kim YS, Han DS, et al. Clinical differences in Clostridium difficile infection based on age: a multicenter study. Scand J Infect Dis. 2014;46:46–51.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55:S65–S70.
   PubMed Web of Science ®Google Scholar
• Rao K, Micic D, Natarajan M, et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins a or b in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015;61:233–241.
   PubMed Web of Science ®Google Scholar
• Shastri YM, Bergis D, Povse N, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med. 2008;121:1099–1106.
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr., Fletcher JG, O'Byrne S, et al. EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol. 2013;108:1891–1900.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index, c-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332–341.
   PubMed Web of Science ®Google Scholar
• Swale A, Miyajima F, Roberts P, et al. Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study. PLoS One. 2014;9:e106118.
   PubMed Web of Science ®Google Scholar
• McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;28:140–145.
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–455.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–498.
   PubMed Web of Science ®Google Scholar
• Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis. 2012;55:1661–1668.
   PubMed Web of Science ®Google Scholar
• Martinson JNV, Broadaway S, Lohman E, et al. Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology. J Clin Microbiol. 2015;53:1192–1197.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55:S93–S103.
   PubMed Web of Science ®Google Scholar
• Lowy I, Molrine DC, Leav BA, et al. Treatment with clostridium difficile toxins. N Engl J Med. 2010;362:197–205.
   PubMed Web of Science ®Google Scholar
• Wilcox M, Gerding D, Poxton I, et al. Bezlotoxumab alone and with actoxumab for prevention of recurrent Clostridium difficile infection in patients on standard of care antibiotics: integrated results of 2 phase 3 studies (MODIFY I and MODIFY II). Open Forum Infect Dis. 2015;2:S3.
   Google Scholar
• Neemann K, Eichele DD, Smith PW, et al. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transplant Infect Dis. 2012;14:E161–E165.
   PubMed Web of Science ®Google Scholar
• Trubiano JA, Gardiner B, Kwong JC, et al. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol. 2013;25:255–257.
   PubMed Web of Science ®Google Scholar
• Gallegos-Orozco J, Paskvan-Gawryletz C, Gurudu S, et al. Successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis. Rev Gastroenterol Mex. 2011;77:40–42.
   Google Scholar
• You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med. 2008;148:632–633.
   PubMed Web of Science ®Google Scholar
• Emanuelsson F, Claesson BEB, Ljungström L, et al. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand J Infect Dis. 2014;46:89–97.
   PubMed Web of Science ®Google Scholar
• Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254:423–429.
   PubMed Web of Science ®Google Scholar
• Bartsch SM, Umscheid CA, Fishman N, et al. Is fidaxomicin worth the cost? an economic analysis. Clin Infect Dis. 2013;57:555–561.
   PubMed Web of Science ®Google Scholar
• Solari PR, Fairchild PG, Noa LJ, et al. Tempered enthusiasm for fecal transplant. Clin Infect Dis. 2014;59:319.
   PubMed Web of Science ®Google Scholar
• Steiner TS, Flores CA, Pizarro TT, et al. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol. 1997;4:719–722.
   PubMedGoogle Scholar
• El Feghaly RE, Stauber JL, Deych E, et al. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis. 2013;56:1713–1721.
   PubMed Web of Science ®Google Scholar
• Rao K, Walk ST, Micic D, et al. Procalcitonin levels associate with severity of Clostridium difficile infection. PLoS One. 2013;8:e58265.
   PubMed Web of Science ®Google Scholar
• LaSala PR, Ekhmimi T, Hill AK, et al. Quantitative fecal lactoferrin in toxin-positive and toxin-negative Clostridium difficile specimens. J Clin Microbiol. 2013;51:311–313.
   PubMed Web of Science ®Google Scholar
• Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis. 2013;13:936–945.
   PubMed Web of Science ®Google Scholar
• Kaltsas A, Simon M, Unruh LH, et al. Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. J Clin Microbiol. 2012;50:1303–1307.
   PubMed Web of Science ®Google Scholar
• Longtin Y, Trottier S, Brochu G, et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis. 2013;56:67–73.
   PubMed Web of Science ®Google Scholar
• Wang Y, Atreja A, Wu X, et al. Similar outcomes of IBD inpatients with Clostridium difficile infection detected by ELISA or PCR assay. Dig Dis Sci. 2013;58:2308–2313.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol. 2013;51:869–873.
   PubMed Web of Science ®Google Scholar
• Brown NA, Lebar WD, Young CL, et al. Diagnosis of Clostridium difficile infection: comparison of four methods on specimens collected in Cary-Blair transport medium and tcdB PCR on fresh versus frozen samples. Infect Dis Rep. 2011;3:e5.
   PubMedGoogle Scholar
• Rao K, Erb-Downward JR, Walk ST, et al. The systemic inflammatory response to Clostridium difficile infection. PLoS One. 2014;9:e92578.
   PubMed Web of Science ®Google Scholar